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Re-vaccination of 421 children with a past history
of an adverse vaccine reaction in a special
immunisation service
Michael Gold, Helen Goodwin, Sue Botham, Margaret Burgess, Margot Nash,
Ann Kempe
Abstract
Background—In Australia an adverse
event following immunisation (AEFI),
with the exception of anaphylaxis and
encephalopathy, is no longer considered
an absolute contraindication to continu-
ing vaccination with the suspect vaccine.
Despite these recommendations there is a
paucity of information on the re-
vaccination of such children.
Aims—To describe the re-vaccination of a
large number of children with a past
history of an AEFI.
Methods—A review of children attending
special immunisation services in three
Australian tertiary care paediatric cen-
tres.
Results—During the review 970 children
attended of whom 469 had experienced a
past AEFI. Of these, 293 had experienced
minor while 176 children had experienced
significant neurological or allergic reac-
tions. The majority (421/469) were re-
vaccinated, with only one child having a
significant neurological event; this was
transient and resolved spontaneously.
Conclusions—Re-vaccination of children
who have a past history of an AEFI
appears safe. A special immunisation
service should be part of a comprehensive
immunisation programme.
(Arch Dis Child 2000;83:128–131)
Keywords: immunisation; adverse event following
immunisation; adverse vaccine reactions
Concerns about vaccine safety are of crucial
importance to parents and vaccine providers,
particularly in countries where vaccine pre-
ventable disease (VPD) is uncommon.1 Vac-
cines are not devoid of risk, and minor adverse
reactions following childhood vaccination, es-
pecially vaccines containing pertussis antigens,
are common.2 Fortunately serious adverse
reactions are rare and the risk of morbidity
from such reactions is far less than that which
may occur following a VPD. Ironically while
concerns have been increasing about vaccine
safety, the contraindications to re-vaccination,
in children who experience an adverse reac-
tion, have been reduced. In Australia and the
USA, anaphylaxis and encephalopathy are now
considered the only conditions that are an
absolute contraindication to re-vaccination
with the suspect vaccine.3–6 In these countries
an adverse event following immunisation
(AEFI) such as a severe local reaction, high
fever, screaming, convulsion, or hypotonic
hyporesponsive episode (HHE) is no longer
considered an absolute contraindication. De-
spite these recommendations it is likely that
many children who have experienced such
reactions do not complete their immunisation
schedule. In Australia pertussis vaccine was
frequently omitted from the immunisation
schedule, prior to the introduction of acellular
pertussis vaccine, and this was reflected in the
widespread use of a combined diphtheria–
tetanus vaccine.5 This is of concern given the
recent epidemic of pertussis in Australia with at
least 10 668 cases notified in 1997.7
In the late 1980s special immunisation serv-
ices (SIS) were established in the UK to review
and promote the vaccination of children with
an existing medical disorder, egg allergy, or
those with a perceived contraindication to vac-
cination or a past history of an AEFI.8 9 Within
Australia a SIS was first established in 1994.10
However, these earlier services have reported
only small numbers of children and do not
reflect the current practice of oVering continu-
ing vaccination, including acellular pertussis
vaccine, to those children who have experi-
enced serious reactions which were then
regarded as containdications. Similar SIS have
been established in three tertiary care paediat-
ric hospitals in Australia. The aim of this report
was to describe the re-vaccination of a larger
number of children who have attended these
services with a past history of an AEFI.
Methods
This was a retrospective review of children
attending the SIS in South Australia (Women’s
and Children’s Hospital, Adelaide), New
South Wales (New Children’s Hospital, Syd-
ney), and Victoria (Royal Children’s Hospital
and Monash Medical Centre, Melbourne).
The overall period of review was from October
1996 to March 1999. The routine childhood
immunisation schedule in place at the time was
for diphtheria, tetanus, and pertussis (DTP),
Haemophilus influenzae type b (HiB), and oral
polio (OPV) vaccines to be administered at 2,
4, and 6 months of age. Measles, mumps, and
rubella (MMR) vaccine was administered at 12
months of age followed by booster doses of
DTP and HiB at 18 months. Between 4 and 5
years of age DTP and OPV were administered.
In August 1997 a three component acellular
containing pertussis vaccine (Infanrix; Smith-
Kline Beecham, Melbourne) was licensed for
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use in Australia and by 1999 this vaccine
replaced the use of whole cell pertussis vaccine.
However, from August 1997 children who pre-
sented with an AEFI, to the SIS, associated
with DTPw (whole cell pertussis) were oVered
re-vaccination with DTPa (acellular pertussis)
if this was appropriate.
Each SIS was promoted locally as a service
for children with a prior history of an AEFI or
an underlying medical disorder which may
have precluded immunisation. Children at-
tending were referred by a health professional
(consultant paediatrician, or medical or nurse
practitioner). The following features were
common to all services. Firstly, all children
were reviewed by a paediatrician with a special
interest and expertise in immunisation. Sec-
ondly, vaccines were administered according to
guidelines detailed in the National Health and
Medical Research Council Australian Immuni-
sation handbook.4 Re-vaccination with the sus-
pect vaccine was considered to be contraindi-
cated if the presenting event was anaphylaxis or
encephalopathy (for vaccines containing per-
tussis, measles, mumps, or rubella antigens).
All other children were oVered re-vaccination
with the suspect vaccine if these vaccines were
due, the child was not acutely unwell with a
fever (body temperature above 38.5°C), and
neither the child (for MMR and OPV) nor any
household contacts (for OPV) were immuno-
suppressed. Parental valid consent was ob-
tained following a discussion of the risks and
benefits of re-vaccination. Thirdly, each child
was observed following vaccination. Those
considered at high risk were observed in hospi-
tal for a period of between four and eight hours.
In a minority of cases children were admitted
for overnight observation. Lastly, parents of
those children who were immunised were
telephoned between 24 and 72 hours after vac-
cination and questioned about any symptoms
their child had developed. In Adelaide and
Melbourne parents were also contacted seven
days after vaccination, while in Sydney this
only occurred if an AEFI was reported during
the first telephone contact. At follow up a
standard telephone questionnaire was adminis-
tered inMelbourne while parents were asked to
report any adverse events at the remaining two
sites.
Data were collated from each service,
including the total number of patients attend-
ing, their ages and sex, the proportion of those
with an AEFI, the nature of the AEFI and vac-
cines associated with the reaction, the vaccines
administered in the SIS, and the outcome of
vaccination in the service. The presenting
AEFIs were divided into local reactions, fever
(of any degree), irritability, screaming (un-
specified), vomiting, or diarrhoea. These reac-
tions often occurred concurrently and were
analysed together. Reactions such as convul-
sions (within seven days of a vaccine), HHE,
skin rash (usually urticarial and not associated
with thrombocytopenia, anaphylaxis, or vac-
cine viraemia), or anaphylaxis were considered
primary reactions regardless of any other
symptoms reported. HHE was defined as a
sudden event occurring within 48 hours of
vaccination characterised by hypotonia, hy-
poresponsiveness, and pallor in the absence of
a known cause such as a convulsion.11 An AEFI
was recorded to the vaccines administered in
the SIS if the parents reported any symptoms
in the seven day period post-vaccination.
Results
During the period of review 970 children
attended the three SIS of whom 469 (48%) had
experienced a prior AEFI, with the remainder
having an underlying medical disorder (includ-
ing egg anaphylaxis) which led to concerns
regarding immunisation. Of those presenting
with an AEFI, 55% were boys, with a median
age 24 months (range 1 to 183 months), often
indicating a considerable delay in the interval
between the AEFI and review. Table 1 presents
details of the vaccines associated with each
AEFI. Of the 469 children with an AEFI, 293
(63%) had a history of a local reaction, fever,
irritability, screaming, vomiting, or diarrhoea
post-vaccination. The remaining 176 (37%)
children presented with HHE, convulsions,
skin rash (usually urticarial and not associated
with thrombocytopenia, anaphylaxis, or vac-
Table 1 Details of previous adverse event following immunisation and vaccine(s) associated with the event in 469 children
attending the SIS











OPV MMR Hep B
CDT +/−
OPV BCG Total (% of total)
Fever, local reactions,
screaming, other* 274 10 3 2 1 3 293 (63%)
HHE 75 5 1 81 (17%)
Convulsions 38 1 2 1 42 (9%)
Skin rash 21 6 2 6 35 (8%)
Anaphylaxis 2 3 5 (0.5%)
Apnoea 4 1 5 (0.5%)
Serious other† 6 1 1 8 (2%)
Total 420 21 5 10 9 3 1 469 (100%)
*Other includes lethargy, vomiting, diarrhoea, and drowsiness.
†Serious other: one case each of monoparesis, hepatitis, BCG abscess, cerebral haemorrhage, encephalopathy, thrombocytopenia,
bronchospasm without anaphylaxis, episode of cyanosis.
DTPw and a, diphtheria, tetanus, and whole cell/acellular pertussis; Pa, monovalent acellular pertussis; CDT, diphtheria, tetanus;
HiB,Haemophilus influenzae B; OPV, oral polio vaccine;MMR,measles, mumps, and rubella; Hep B, hepatitis B; BCG, Bacille Cal-
mette Guérin.
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cine viraemia), anaphylaxis, apnoea, or a
number of miscellaneous symptoms. In 420/
469 (90%) children the AEFI was associated
with administration of DTPw vaccine. In these
children DTPw was given alone or in combina-
tion with Hib, OPV, or hepatitis B (Hep B)
vaccines. The remaining 48/469 (10%) of
AEFIs were associated with the administration
of DTPa, MMR, HiB, OPV, Hep B, and CDT
(combined diphtheria and tetanus) vaccines.
Following clinical review 421/469 (90%)
children were vaccinated in the SIS. Table 2
shows details of the vaccines administered to
each child, for each presenting AEFI. Of the
421 children vaccinated, 257 received DTPa
and 94 a monovalent acellular pertussis vaccine
with or without diphtheria, tetanus, Hib,
MMR, OPV, or Hep B vaccines. Forty eight
(10%) children were not vaccinated following
clinical review. However, in seven of these chil-
dren (five with anaphylaxis, one with encepha-
lopathy, one with thrombocytopenia) further
vaccination with the suspect vaccine was
contraindicated or not due, and in 18 children
no further doses of the suspect vaccine were
due. The parents of only 13 children refused
the recommended vaccinations or failed to
reattend the service to receive them.
Of the 421 children vaccinated, 350 (83%)
experienced no subsequent AEFI. Seventy
children (17%) experienced fever and/or a
local reaction and/or lethargy within the seven
day period post-vaccination. One of these 70
children required hospital admission four days
following vaccination with an acellular pertus-
sis vaccine. This child was subsequently
diagnosed as having a lobar pneumonia which
improved following intravenous penicillin.
Only one of the 421 children vaccinated in the
SIS experienced a significant AEFI and is likely
to have experienced an HHE following re-
vaccination. This child attended the SIS
because he experienced fever, pallor, and
irritability with screaming at 2 months of age
following his first DTPw vaccine. At 4 months
of age and following review in the SIS he was
vaccinated with DTPa, HiB, and OPV vaccine.
Approximately five hours after the vaccination
he became pale and hypotonic. This resolved
spontaneously and no hospital admission was
required. Subsequent to this event the child
received a further DTPa vaccine without
sequelae.
Of particular interest was the re-vaccination
of children who presented with significant
neurological reactions (HHE, convulsions,
apnoea). In all 101 of the 130 children (78%),
those who experienced these reactions post-
vaccination with a pertussis containing vaccine
were re-vaccinated with either a whole cell or
acellular pertussis containing vaccine. All but
five of these children received DTPa and none
of these children experienced a recurrence of a
significant AEFI.
Discussion
Communicating to parents the relative risks
and benefits of vaccination is essential when
deciding whether to vaccinate a child.12 In chil-
dren who have experienced an AEFI it is diY-
cult for vaccine providers and parents to make
this risk–benefit assessment when considering
re-vaccination with the suspect vaccine. Al-
though the benefits from immunisation may be
easily defined, an assessment of risk is diYcult.
Firstly, there is a paucity of information about
the risk of an AEFI recurring in such children.
Secondly, a poor understanding of the patho-
genesis of many AEFI, the lack of identifiable
risk factors in individual children, and the
uncommon occurrence of significant AEFI
further complicates such assessments. Clinical
vaccine studies and post-marketing surveil-
lance provide an indication of the frequency of
adverse reactions in the general population.
They do not define the risk of recurrent
reactions in children who have experienced an
AEFI.The information presented in this report
may help vaccine providers and parents to
determine more accurately the risk of re-
vaccinating children who have experienced an
AEFI.
The majority of children who were seen in
these services presented with fever, a local
reaction, and/or screaming although a number
had experienced a significant neurological
Table 2 Details of vaccines administered to 421 children, with a past history of an adverse event following immunisation,
attending the SIS


























screaming, other* 17 163 68 3 2 6 7 2 269 92
HHE 2 54 12 3 1 72 89
Convulsions 1 20 8 1 4 1 35 83
Skin rash 6 14 4 1 2 3 3 33 94
Anaphylaxis 2 1 3 60
Apnoea 3 1 4 80
Other serious† 3 1 1 5 63
Total 26 257 94 8 5 10 16 6 421 90
*Other includes lethargy, vomiting, diarrhoea, and drowsiness.
† Serious other: one case each of monoparesis, hepatitis, thrombocytopenia, bronchospasm without anaphylaxis, episode of cyano-
sis.
DTPw and a, diphtheria, tetanus, and whole cell/acellular pertussis; Pa, monovalent acellular pertussis; CDT, diphtheria, tetanus;
HiB,Haemophilus influenzae B; OPV, oral polio vaccine;MMR,measles, mumps, and rubella; Hep B, hepatitis B; BCG, Bacille Cal-
mette Guerin.
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reaction (HHE, convulsions, apnoea, mon-
oparesis, and encephalopathy). The whole cell
pertussis component of the DTPw vaccine was
thought to be associated with the majority of
these reactions as the reactogenicity of this
vaccine is well documented. Successful re-
vaccination, with a vaccine containing acellular
pertussis vaccine, occurred in most of these
children. These findings further support a
recent study from the Netherlands which
investigated the risk of recurrence of HHE fol-
lowing repeat vaccination with a whole cell
pertussis vaccine.13 In this study 84 children
with a past history of HHE received 236 doses
of whole cell pertussis vaccine, with no child
experiencing a recurrence. However, recur-
rences of HHE have been documented follow-
ing re-vaccination with whole cell pertussis
vaccine and it has been suggested that
re-vaccination should be avoided.14 The find-
ings of our study suggest that acellular pertus-
sis vaccine is a safe alternative in those children
who have experienced significant neurological
reactions following a whole cell pertussis
vaccine. This is consistent with recent surveil-
lance data from South Australia which show
that minor and serious reactions and reactions
requiring medical and hospital review were
three times less common with a three compo-
nent acellular pertussis vaccine than with a
whole cell pertussis vaccine.15 In Australia
DTPa has now replaced DTPw, and it remains
to be seen if children presenting with AEFIs
associated with DTPa administration can be
successfully re-vaccinated using this vaccine.
It is clear that this cohort of children is a
selective sample as the services did not capture
all children who experienced an AEFI. In Aus-
tralia vaccine coverage for three doses of
pertussis-containing vaccines is estimated to be
around 80%, which is considered suboptimal
and lower than rates in the UK and the USA.16
The exact rate of AEFIs in Australia was not
known nor was it known how many children
with AEFIs were referred to a SIS and
subsequently assessed. Ideally, the service
would need to review a larger sample of
children who experience an AEFI and deter-
mine the outcome of re-vaccination.
Nevertheless, the vast majority of children
attending these services in whom vaccination
was indicated, were successfully re-vaccinated.
This indicates that the parents attending the
services were highly motivated to continue or
complete their child’s immunisation schedule.
Further research is required to ascertain what
factors determine which parents presented for
review and whether this sample is representa-
tive of all children who have experienced an
AEFI.
We consider that an SIS should be an essen-
tial component of an immunisation pro-
gramme. Firstly, an SIS facilitates the contin-
ued immunisation of children who have
experienced an AEFI. It was the anecdotal
impression of the authors that many of these
children would not have continued with the
immunisation schedule or sought catch up
vaccination were it not for the SIS. This delay
would increase the risk of vaccine preventable
disease in these children and their communi-
ties. The SIS allowed the parents time to
discuss the relative risks and benefits of
re-vaccination with the suspect vaccine. In
addition, parents were reassured that, if need
be, their child could be observed and managed
in hospital post-vaccination. Secondly, an SIS
can be used to enhance the post-marketing
surveillance of AEFI, thereby ensuring vaccine
safety. The SIS should encourage parents and
vaccine providers to refer children who have
experienced a significant AEFI where further
advice is needed by the parent and/or the vac-
cine provider. Clinical review in the SIS further
clarifies the true nature of such reactions.
Thirdly, the service conveys an important mes-
sage to parents, vaccine providers, and the gen-
eral community that AEFI do occur, are taken
seriously by health providers, but rarely
contraindicate further doses. This is of particu-
lar importance in counteracting the false claims
of anti-immunisation groups which have a par-
ticular focus on AEFI.17 Lastly, an SIS should
enhance current research regarding the clinical
management and investigation of children with
AEFI. The potential public health and indi-
vidual benefits of an SIS need to be considered
in planning a comprehensive immunisation
programme.
We are grateful to Lindy Harkness, Claire Nayda, and Maggi
Osbourn for assistance with the Special Immunisation Service
(South Australia).
1 Chen R, Hibbs B. Vaccine safety: current and future
challenges. Pediatr Ann 1998;27:445–54.
2 Decker MD, Edwards KM, SteinhoV MC, et al. Compari-
son of 13 acellular pertussis vaccines: adverse reactions.
Pediatrics 1995;96(suppl 3):557–66.
3 The Australian College of Paediatrics. Policy statement.
Contraindications to immunization against pertussis. J
Paediatr Child Health 1994;30:310–11.
4 National Health and Medical Research Council. The
Australian immunisation handbook, 6th ed. Canberra:
AGPS, 1997.
5 Burgess M, McIntyre P, Heath T. Rethinking the contrain-
dications to vaccination.Med J Aust 1998;168:476–7.
6 Advisory Committee on Immunization Practice. MMWR
Morb Mortal Wkly Rep 1994;43:24–5.
7 O’Brien E, D’Souza R, Gillroy N, et al. Australia’s notifiable
disease status, 1997. Commun Dis Intell 1999;23:1–27.
8 Ko MLB, Rao M, Teare L, et al. Outcome of referrals to a
district immunisation advisory clinic. Commun Dis Rep
1995;5:R146-9.
9 Newport MJ, Conway SP. Experience of a specialist service
for advice on childhood immunisation. J Infect 1993;26:
295–300.
10 Andrews RM, Kemp AE, Sinn KK, Herceg A. Vaccinating
children with a history of serious reactions after vaccination
or of egg allergy.Med J Aust 1998;168:491–4.
11 Braun MM,Terracciano G, Salive ME, et al. Report of a US
public health workshop on hypotonic hyporesponsive
episode (HHE) after pertussis immunisation. Pediatrics
1998;102:e52.
12 Ball LK, Evans G, Bostrom A. Risky business: challenges in
vaccine risk communication. Pediatrics 1998;101:453–8.
13 Vermeer-de Bondt PE, Labadie J, Rumke HC. Rate of
recurrent collapse after vaccination with whole cell pertusis
vaccine: follow-up study. BMJ 1998;316:902–3.
14 Tozzi AE, Ciofi delgi Atti ML, Salmaso S, Anemona A.
Repeat whole cell vaccinations should be avoided after
hypotonic hyporesponsive epiosdes. BMJ 1988;317:604.
15 Gold M, Osbourne M, Kempe A. A comparison of serious
adverse reactions to whole cell and acellular pertussis vac-
cines in South Australia.Med J Aust 1999;171:285.
16 Lister S, McIntyre PB, Burgess MA, O’Brien ED. Immuni-
sation coverage in Australian children: a systematic review
1990–1998. Commun Dis Intell 1999;23:145–70.
17 Leask JA, Chapman S. “An attempt to swindle nature”:
press anti-immunisation reportage 1993–1997. Aust N Z J
Public Health 1998;22:17–26.
Re-vaccination of children with a previous adverse vaccine reaction 131
www.archdischild.com
 on 28 August 2008 adc.bmj.comDownloaded from 
